• ALK presented new EAACI 2026 Congress data pointing to weak real-world adherence to adrenaline auto-injectors among people at risk of anaphylaxis.
• Survey findings showed many patients do not regularly carry or use prescribed injectors, leaving gaps in emergency readiness.
• Across patient preference testing and simulated-use research, EURneffy needle-free nasal adrenaline was favored over injectors for ease of use.
• Participants indicated they would dose sooner with the nasal spray than with an auto-injector, suggesting potential to reduce hesitation in emergencies.
• Clinicians rated the nasal spray stronger on portability and adherence-related attributes, while maintaining higher confidence in injector efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALK-Abelló A/S published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.